THE DRUG DOCKETIn a 180-infant phase 1/2 trial, a live-attenuated intranasal RSV vaccine raised neutralising antibodies in two-thirds or more of RSV-naive babies but barely budged those already exposed. Sanofi funded the study.
3 min read
A final order published 9 October classifies the over-the-counter infant pulse rate and oxygen saturation monitor as class II, with special controls built around the risk that it fails to detect a pulse.
3 min read
WHAT THE STUDY ACTUALLY SAYSA register-based study spanning 181,999 infants and four RSV seasons found acute otitis media dropped 44% and RSV detections 83% in infants under 12 months after a nirsevimab immunisation programme began.
3 min read
WHAT THE STUDY ACTUALLY SAYSA test-negative study across seven paediatric hospitals in Ontario and Quebec, run after a publicly funded rollout, estimated 78% effectiveness against laboratory-confirmed RSV and 97% against intensive-care admission.
4 min read
EXPLAINERPositional flat head affects nearly half of two-month-olds and is usually mild. In the one randomised trial, moulding helmets matched the natural course — and every parent reported a side effect.
3 min read
EXPLAINERBringing up milk is normal in healthy babies: it peaks around four months and usually fades by the first birthday. Most infants need no medicine, and the evidence for acid-suppressing drugs in simple reflux is weak.
3 min read
WHAT THE STUDY ACTUALLY SAYSThe SMART trial tested clesrovimab against palivizumab in premature and heart- and lung-affected infants. It was built to show safety, not to prove one prevents more RSV than the other.
3 min read
WHAT THE STUDY ACTUALLY SAYSA Buenos Aires surveillance cohort estimates 80.8% effectiveness against RSV hospitalisation in infants under three months — close to what the licensing trial found, in a real programme.
3 min read